Company profile
Aion Therapeutic Inc.
OTC: ANTCF · Healthcare · Drug Manufacturers - Specialty & Generic
Canadian filerHQ Vancouver, ONReports USD
#982 of 1,422 Healthcare companies by revenue
EA Score
——FH —DQ —GM —SS 24
v0.1 · 5/100 weight · pillars only
↑ disclosure history, Piotroski F · ↓ return on assets, balance-sheet leverage
Methodology →Revenue TTM
$1.1M
Rev growth YoY (TTM)
+547.6%
Net income (FY)
-$4.7M
Employees
5
as of 2026-08-25
Market cap
$2.1M
as of 2026-08-25
Financials — latest annual
SEC EDGAR · USD-normalizedConceptUSDNativeFY
Revenue$272.1k367.5k CAD2024
Net income-$4.7M-6.3M CAD2024
Operating income-$882.0k-1.2M CAD2024
Total assets$511.3k702.9k CAD2024
Liabilities$3.3M4.6M CAD2024
Equity-$2.8M-3.9M CAD2024
Revenue trend
FY2017 – FY2024 · USD
FY17
FY18
FY19
FY20
FY21
FY22
FY23
FY24
Revenue by segment
No segmentation disclosed for this filer. n/a
The read
What is Aion Therapeutic Inc.’s revenue?
Aion Therapeutic Inc. booked $272.1k in FY2024 revenue — among the slowest-growing Healthcare companies we track, at a -1710.9% net margin.
Peers · Healthcare
Motus GI Holdings, Inc.——CannAmerica Brands Corp.——Hydrogen Hybrid Technologies, Inc.——Abattis Bioceuticals Corp.——Entia Biosciences, Inc.——CEL-SCI Corporation32DKey facts
CEOJohn Graham Simmonds Jr.
SectorHealthcare
IndustryDrug Manufacturers - Specialty & Generic
HeadquartersVancouver, ON
ExchangeOTC: ANTCF
Employees5
IPO date2021-04-21
Latest filings
No filings loaded — no CIK (non-SEC filer).
Financials: SEC EDGAR (XBRL), USD-normalized per IAS 21 · TTM/quarterly + segments: FMP from filed disclosures · Filings: EDGAR submissions. County headcount and EA Score are in progress — see docs/DATA_GAPS.md.